Inhibitors of cathepsin K: A patent review (2004 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 10, 2011, Pages 1611-1629

  Wijkmans, Jac ^a   Gossen, Jan ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD   (Netherlands)

Author keywords

Cathepsin K; Cysteine protease inhibitor; Lysosomotropic behavior; Odanacatib; Osteoporosis; Reversible binding; Warhead

Indexed keywords

6 PHENYL 1H IMIDAZO[4,5 C]PYRIDINE 4 CARBONITRILE DERIVATIVE; AM 3701; ANTINEOPLASTIC AGENT; BALICATIB; BENZENESULFONIC ACID DERIVATIVE; CATHEPSIN K; CATHEPSIN K INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HEXAHYDRO 2 OXA 1,4 DIAZA PENTALENE 6 ONE; HEXAHYDROPYRROLO[3,2 B]PYRROL 3 ONE; HEXAHYDROPYRROLO[3,2 C]PYRAZOL 6 ONE; KETONE DERIVATIVE; L 006235; L 873724; MIV 710; MIV 711; MV 074942; MV 076159; N CYANOMETHYLBENZAMIDE; NITRILE; ODANACATIB; ONO 5334; PYRROLOPYRIMIDINE DERIVATIVE; RELACATIB; TETRAHYDROFURO[3,2 B]PYRROL 3 ONE; TETRAHYDROFURO[3,2 C]ISOXAZOL 6 ONE; TETRAHYDROFURO[3,2 C]PYRAZOL 6 ONE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

BREAST CANCER; DRUG ERUPTION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ELECTROPHILICITY; ENZYME INHIBITION; HUMAN; NONHUMAN; OSTEOPOROSIS; PATENT; PROTEIN STRUCTURE; REVIEW; SKIN FIBROSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; BONE RESORPTION; CATHEPSIN K; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; OSTEOPOROSIS; PATENTS AS TOPIC;

EID: 80053049819     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.616283     Document Type: Review

References (117)

1. Gupta S, Kumar Singh R, Dastidar S, et al. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin Ther Targets 2008;12:291-9 (Pubitemid 351419423)
2. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005;52:1-9
3. Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 2008;83:172-6
4. Xiao Y, Junfeng H, Tianhong L, et al. Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity. J Clin Endocrinol Metab 2006;91:4520-7 (Pubitemid 44833434)
5. Yang M, Sun J, Zhang T, et al. Deficiency and inhibition of cathepsin K reduce body weight and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol 2008;28:2202-8
6. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8
7. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654-63 (Pubitemid 29455813)
8. Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8
9. Yamada H, Mori H, Nakanishi Y, et al. Orally active cathepsin K inhibitor, ONO-5334, potently improved bone mineral density not only in trabecular bone but also in cortical bone in ovariectomized cynomolgus monkeys. J Bone Miner Res 2009;24(Suppl 1). Available from: http://www.asbmr.org/ Meetings/ AnnualMeeting/AbstractDetail.aspx? aid=adea5452-dfae-4b23-954b- 18d08f157557
10. Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the Cathepsin K inhibitor, ONO-5334, in postmenopausal osteoporosis - the OCEAN study. J Bone Miner Res 2011;26:1303-12
11. Bennypacker BL, Duong le T, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2011;26:252-62
12. McCracken P, Jayaka R, Purcell M, et al. A multi-modality imaging comparison of odanacatib to alendronate in the ovariectomized rhesus monkey. J Bone Miner Res 25 (Suppl 1). Available from: http://www. asbmr.org/Meetings/ AnnualMeeting/ AbstractDetail.aspx?aid=fce93bbc-5a41- 42b1-b2a6-d74a5fc1dcf1
13. Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26:242-51
14. Binkley N, Bone H, Eisman J, et al. Effect of odanacatib on bone density and bone turnover markers in postmenopausal women with low bone mineral density: year 4 results. J Bone Miner Res 25(Suppl 1): Available from: http://www.asbmr.org/ Meetings/AnnualMeeting/Abstract Detail.aspx?aid=a431b2ef- f2b9-4c0d- 8f7b-8d0fa50da6f4
15. Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporosis Int 2011;DOI: 10.1007/s00198-011-1529-x
16. Novinec M, Kovacic L, Lenarcic B, et al. Conformational flexibility and allosteric regulation of cathepsin K. Biochem J 2010;429:379-89
17. McGrath ME, Klaus JL, Barnes MG, et al. Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat Struct Biol 1997;4:105-9 (Pubitemid 27066383)
18. Black WC, Peptidomimetic inhibitors of cathepsin K. Curr Top Med Chem. 2010;10:745-51
19. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of adanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18:923-8 (Pubitemid 351179363)
20. Peters J-U. 11 Years of Cyanopyrrolidines as DPP-IV inhibitors. Curr Top Med Chem 2007;7:579-95 (Pubitemid 46499209)
21. Kuhn B, Hennig M, Mattei P. Molecular recognition of ligands in dipeptidyl peptidase IV. Curr Top Med Chem 2007;7:609-19 (Pubitemid 46488283)
22. Smith WS, Abdel-Meguid SS. Cathepsin K as a target for the treatment of osteoporosis. Expert Opin Ther Patents 1999;9:683-94 (Pubitemid 29259655)
23. Frizler M, Stirnberg M, Sisay MT, et al. Development of nitrile-based peptidic inhibitors of cysteine cathepsins. Curr Top Med Chem 2010;10:294-322
24. Deaton DN, Tavares FX. Design of cathepsin K inhibitors for osteoporosis. Curr Top Med Chem 2005;5:1639-75
25. Bromme D, Lecaille F. Cathepsin K Inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009;18:585-600
26. Cai J, Jamieson C, Moir J, et al. Cathepsin K inhibitors, 2000 - 2004. Expert Opin Ther Patents 2005;15:33-48
27. Smith AJT, Zhang X, Leach AG, et al. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J Med Chem 2009;52:225-33
28. Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. J Med Chem 2009;52:1231-46
29. Lucas EC, Williams A. pH dependencies of individual rate constants in papain-catalyzed reactions. Biochemistry 1969;8:5125-35
30. Dufour E, Storer AC, Menard R. Peptide aldehydes and nitriles as transition state analog inhibitors of cysteine proteases. Biochemistry 1995;34:9136-43
31. Black WC, Percival MD. The consequences of lysosomotropism on the design of selective cathepsin inhibitors. ChemBioChem 2006;7:1525-35 (Pubitemid 44555997)
32. Altmann E, Aichholz R, Betschart C, et al. Dipeptide nitrile inhibitors of Cathepsin K. Bioorg Med Chem Lett 2006;16:2549-54
33. Palmer JT, Bryant C, Wang D-X, et al. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of Cathepsin K. J Med Chem 2005;48:7520-34 (Pubitemid 41698795)
34. Novartis AG. Combinations of a cathepsin K inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss. WO05014006; 2005
35. Novartis AG. The use of cathepsin K inhibitors in severe bone loss diseases. WO05049028; 2005
36. Falgueyret J-P, Desmarais S, Oballa R, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 2005;48:7535-43 (Pubitemid 41698796)
37. Adami S, Supronik J, Hala T, et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res 2006;21:S24
38. Sanofi-Aventis. Spirocyclic nitriles as protease inhibitors. WO07137738; 2007
39. Black WC, Bayly CI, Davis DE, et al. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K. Bioorg Med Chem Lett 2005;15:4741-4 (Pubitemid 41354798)
40. Li CS, Deschenes D, Desmarais S, et al. Identification of a potent and selective non-basic Cathepsin K-inhibitor. Bioorg Med Chem Lett 2006;16:1985-9 (Pubitemid 43267393)
41. Merck Frosst Canada & Co., Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors. WO03075836; 2003
42. Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors. WO05019161; 2005
43. Merck Frosst Canada & Co. Cathepsin inhibitors. WO05021487; 2005
44. Merck Frosst Canada & Co. Cathepsin K inhibitors and obesity. WO06076796; 2006
45. Merck Frosst Canada & Co. Cathepsin K inhibitors and atherosclerosis. WO06076797; 2006
46. Merck & Co., Inc. and Merck Frosst Canada Ltd. Formulations for cathepsin K inhibitors. WO08106059; 2008
47. Merck & Co., Inc., Merck Frosst Canada Ltd. Compositions for inhibition of cathepsin K. WO07046842; 2007
48. Merck Frosst Canada Ltd. Amidation process for the preparation of cathepsin K inhibitors. WO08119176; 2008
49. Axys Pharmaceuticals. Processes and intermediates for preparing cysteine protease inhibitors. WO06034004; 2006
50. Merck & Co., Inc. Cathepsin cysteine protease inhibitors. US060111440; 2006
51. Isabel E, Bateman KP, Chauret N, et al. The discovery of MK-0674, an orally bioavailable Cathepsin K inhibitor. Bioorg Med Chem Lett 2010;20:887-92
52. Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors. WO08116302; 2008
53. Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors. WO05000800; 2005
54. Crane SN, Black WC, Palmer JT, et al. beta-Substituted cyclohexanecarboxamide: A nonpeptidic framework for the design of potent inhibitors of cathepsin K. J Med Chem 2006;49:1066-79 (Pubitemid 43221654)
55. Robichaud J, Bayly CI, Black WC, et al. beta-Substituted cyclohexanecarboxamide cathepsin K inhibitors: modification of the 1,2-disubstituted aromatic core. Bioorg Med Chem Lett 2007;17:3146-51 (Pubitemid 46702612)
56. Robichaud J, Black WC, Therien M, et al. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis. J Med Chem 2008;51:6410-20
57. Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors. WO07003056; 2007
58. AstraZeneca UK Ltd. Cyanocyclopropylcarboxamides as cathepsin inhibitors. WO09001127; 2009
59. AstraZeneca UK Ltd. 1,2-Cyclohexane dicarboxamides as cathepsin inhibitors. WO09001128; 2009
60. AstraZeneca UK Ltd. 1-Cyanocyclopropyl-derivatives as cathepsin K inhibitors. WO09001129; 2009
61. Teno N, Masuya K. Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold. Curr Top Med Chem 2010;10:752-66
62. Novartis. Spiro-substituted pyrrolopyrimidines. WO04076455; 2004
63. Irie O, Kosaka T, Ehara T, et al. Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. J Med Chem 2008;51:5502-5
64. NV Organon. 2-Cyano-1,3,5-triazine- 4,6-diamine derivatives. WO05011703; 2005
65. Rankovic Z, Cai J, Kerr J, et al. Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett 2010;20:524-1527
66. NV Organon. 4-Phenyl-pyrimidine-2- carbonitrile derivatives. WO05121106; 2005
67. NV Organon. 4-Cycloalkyl-pyrimidine- 2-carbonitrile derivatives. WO06040300; 2006
68. NV Organon. 4-Phenyl-6-substitutedpyrimidine- 2-carbonitrile derivatives. WO07039470; 2007
69. NV Organon. 6-Phenyl-1H-imidazo[4,5- c]pyridine-4-carbonitrile derivatives as cathepsin K and S inhibitors. WO07080191; 2007
70. NV Organon. 6-Phenyl-1H-imidazo[4,5- c]pyridine-4-carbonitrile derivatives as cathepsin inhibitors. WO09010491; 2009
71. Glaxo Group Ltd. Novel cysteine protease inhibitors. WO07025774; 2007
72. Glaxo Group Ltd. Novel cysteine protease inhibitors. WO07025775; 2007
73. Glaxo Group Ltd. Novel cysteine protease inhibitors. WO07025776; 2007
74. Glaxo Group Ltd. Novel substituted pyrimidines as cysteine protease inhibitors. WO08052934; 2008
75. AstraZeneca UK Ltd. Pteridine derivatives and their use as cathepsin inhibitors. WO07148064; 2007
76. Yamashita DS, Marquis RW, Xie R, et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one Cathepsin K inhibitors. J Med Chem 2006;49:1597-612 (Pubitemid 43376505)
77. Boyd MJ, Crane SN, Robichaud J, et al. Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective Cathepsin K inhibitors. Bioorg Med Chem Lett 2009;19:675-9
78. Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors. WO05066159; 2005
79. Quibell M, Benn A, Flinn N, et al. Bycyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one based scaffold: synthesis and cysteinyl proteinase inhibition. Bioorg Med Chem 2004;12:5689-710 (Pubitemid 39304067)
80. Amura Therapeutics Ltd. Furo[3,2-b]pyrrol derivatives. WO08007103; 2008
81. Amura Therapeutics Ltd. Furo[3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors. WO08007109; 2008
82. Amura Therapeutics Ltd. Furo[3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors. WO08007130; 2008
83. Amura Therapeutics Ltd. Tetrahydrofuro[3,2-b]pyrrol-3-one derivatives as inhibitors of cysteine proteinases. WO08007107; 2008
84. Amura Therapeutics Ltd. Tetrahydrofuro[3,2-b]pyrrol- 3-ones as cathepsin K inhibitors. WO08007112; 2008
85. Amura Therapeutics Ltd. Tetrahydrofuro[3,2-b]pyrrol-3- ones as cathepsin K inhibitors. WO08007114; 2008
86. Amura Therapeutics Ltd. Furo[3,2-b]pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. WO08007127; 2008
87. Amura Therapeutics Ltd. Compounds. WO09112839; 2009
88. Amura Therapeutics Ltd. Compounds. WO09087379; 2009
89. Amura Therapeutics Ltd. Tetrahydrofuro[3,2-b]pyrrol-3-one derivatives as inhibitors of cysteine proteases. WO09144450; 2009
90. Amura Therapeutics Ltd. Biologically active compounds. WO07023281; 2007
91. Boros EE, Deaton DN, Hassell AM, et al. Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors. Bioorg Med Chem Lett 2004;14:3425-9 (Pubitemid 38737140)
92. Available from: http://www.amura.co.uk/cms/data2/ Metastasis%20press%20release.pdf
93. Medivir AB. Cysteine protease inhibitors. WO05066180; 2005
94. Medivir AB. Cysteine protease inhibitor salt. WO08034781; 2008
95. Grabowska U, Crespo L, Ivanov V, et al. Design and synthesis of potent, orally bioavailable Cathepsin K inhibitors displaying whole blood stability. MEDI Abstract Book for the 241st National ACS meeting, Anaheim, CA, March 27-31, 2011
96. Medivir AB. Protease inhibitors. WO08114054; 2008
97. Medivir AB. Cysteine protease inhibitors. WO09000877; 2009
98. Medivir AB. Protease inhibitors. WO10034789; 2010
99. Medivir AB. Protease inhibitors. WO10034788; 2010
100. Medivir AB. Protease inhibitors. WO10034790; 2010
101. Lindstrom E, Vrang L, Sedig S, et al. Cathepsin K inhibitors for the treatment of bone metastasis. 10th Int. Conference Cancer-Induced Bone Disease, Sheffield, UK, September 22-25, 2010
102. Ono Pharmaceutical Co., Ltd. Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredients. US7655804; 2010
103. Barrett DG, Boncek VM, Catalano JG, et al. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2005;15:3540-6 (Pubitemid 40942051)
104. Ono Pharmaceutical Co., Ltd. Bone densifying agent characterized by use of cathepsin K inhibitor with PTH. US7632813; 2009
105. Ono Pharmaceutical Co., Ltd. Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredients. US100087442; 2010
106. Altmann E, Green J, Tintelnot-Blomley M. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K - Investigating P1 substituents. Bioorg Med Chem Lett 2003;13:1997-2001 (Pubitemid 36638398)
107. Kim T-S, Tasker AS. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis. Curr Top Med Chem 2006;6:355-60
108. Shinozuka T, Shimada K, Matsui S, et al. 4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors. Bioorg Med Chem Lett 2006;16:1502-5 (Pubitemid 43197510)
109. Shinozuka T, Shimada K, Matsui S, et al. Arylamine based cathepsin K inhibitors: Investigating P3 heterocyclic substituents. Bioorg Med Chem 2006;14:6807-19 (Pubitemid 44307644)
110. Tejin Pharma Ltd. Cysteine protease inhibitor. WO09125861; 2009
111. Tejin Pharma Ltd. Cysteine protease inhibitor. WO09128521; 2009
112. F. Hoffmann-La Roche AG. Cathepsin K inhibitors. WO07014839; 2007
113. Grabowska UB, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discov Devel 2005;8:619-30 (Pubitemid 41224125)
114. Powers JC, Asgian J, Dogan Ekici O, et al. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 2002;102:4639-750
115. Oballa RM, Truchon J-F, Bayly CI, et al. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg Med Chem Lett 2007;17:998-1002 (Pubitemid 46177618)
116. Peters JU, Schnider P, Mattei P, et al. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 2009;4:680-6
117. Rankovic Z, Cai J, Kerr J, et al. Optimisation of 2-cyanopyrimidine inhibitors of Cathepsin K: improving selectivity over hERG. Bioorg Med Chem Lett 2010;20:6237-41